medigraphic.com
ISSN 1561-3119 (Digital)

2013, Número 4

<< Anterior Siguiente >>

Rev Cubana Pediatr 2013; 85 (4)


Tratamiento con medicamentos antiepilépticos en el niño

Pozo AAJ, Pozo LD

Idioma: Español
Referencias bibliográficas: 102
Paginas: 497-516
Archivo PDF: 114.88 Kb.


RESUMEN

El objetivo de este trabajo es realizar una revisión de la literatura sobre el tratamiento con medicamentos antiepilépticos en el niño. Un aspecto importante en el tratamiento de la epilepsia es disminuir o lograr la cesación de las crisis epilépticas para garantizar una calidad de vida adecuada. Existen varios factores que se deben considerar en el momento de seleccionar el primer medicamento antiepiléptico, entre los se encuentran la eficacia relativa, la tolerabilidad, las interacciones medicamentosas y seguridad a largo plazo del fármaco seleccionado, el tipo de crisis epiléptica, el síndrome epiléptico, la edad, el sexo, el peso, las comorbilidades asociadas, entre otros. Si se decide emplear tratamiento adjunto, deben combinarse medicamentos con diferentes mecanismos de acción. Todos los antiepilépticos clásicos o de primera generación son medicamentos eficaces que continúan desempeñando un papel importante en el tratamiento actual de la epilepsia. Estos fármacos en la actualidad se emplean en el tratamiento de primera opción para muchos tipos de crisis epilépticas o síndromes epilépticos. Son pocos los medicamentos antiepilépticos de segunda generación que en la actualidad se consideran de primera elección para el tratamiento de la epilepsia en el niño.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Carpio A, De Bittencourt PR. Epilepsy in the tropic. En: Chopra JS, Sanrey IMS, eds. Neurology in tropic. New Delhi: BI, Churchil Livingstone Put Ltb; 1999. p. 527-32.

  2. Cowan LD, Bodensteiner JB, Leviton A, Doherty L. Prevalence of epilepsy in children and adolescents. Epilepsia. 1989;30:94-106.

  3. Pavlovic M, Jarebinski M, Pekimezovic T, Levic Z. Seizure disorders in preschool children in a Serbian district. Neuroepidemiology. 1998;17:105-10.

  4. Britten N, Morgan K, Fenwick PBC, Britten H. Epilepsy and handicap from birth to age 36. Dev Med Child Neurol. 1986;28:719-28.

  5. Camfield P, Camfield C. Nova Scotia pediatric epilepsy study. En: Jallon P, Berg A, Dulac O, Hauser A, eds. Prognosis of epilepsies. Paris: John Libbey Eurotext; 2003. p. 113-26.

  6. Dulac O. Chirurgie de l'épilepsie de l'enfant et plasticité cérébrale. En: Bureau M, Kahane P, Munari C, eds. Epilepsies partielles graves pharmacorésistantes de l'enfant: stratégies diagnostiques et traitements chirurgicaux. London: John Libbey Eurotext; 1998. p. 15-21.

  7. Guerrini R, Parmeggiani L. Practicioner Review: use of antiepileptic drugs in children. Journal of Child Psychology and Psychiatry. 2006;47:115-26.

  8. Brodie MJ, Kwan P. Staged approach to epilepsy. Neurology. 2002;58:S2-8.

  9. Asconape JJ. The selection of antiepileptic drugs for the treatment of epilepsy in children and adults. Neurol Clin. 2010;28:843-52.

  10. De Silva M, Mc Ardle B, McGowan M, Hughes E, Stewart J, Neville BG, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet. 1996;347:709-13.

  11. French JA, Kauner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs I. Treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62:1252-60.

  12. Verity CM, Hosking G, Gaster DJ. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. The paediatric EPITEG Collaborative Group. Developmental Medicine and Child Neurology. 1995;37:97-108.

  13. Coppola G. Treatment of partial seizures in childhood: an overview. CNS Drugs. 2004;18:133-56.

  14. French JA, Kanwer AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptics drugs II: treatment of refractory epilepsy. Report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62:1261-73.

  15. Mikkelsen B, Birket-Smith G, Holm P, Lund M, Vestermark S, Zander Olsen P. A controlled trial of clonazepam INN (Ro5-4o23, RivotrilR) in the treatment of focal epilepsy and secondary generalized gran mal epilepsy. Acta Neurol Scand. 1975;(Suppl 60):55-61.

  16. Mikkelsen B, Berggreen P, Joensen P, kristensen O, Kohler O, Mikkelsen BO. Clonazepam (RivotrilR) and carbamazepine (TegretolR) in psychomotor epilepsy: a randomized multicenter trial. Epilepsia. 1981;22:415-20.

  17. Canadian study Group for childhood epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia. 1998;39:952-9.

  18. Canadian study group for childhood epilepsy. Bawden HN, Camfield CS, Camfield PR, Cunnigham C, Darwish H, Dooley JM, et al. The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Epilepsy Res. 1999;33:133-43.

  19. Shorvon SD. The use of clobazam, midazolam and nitrazepam in epilepsy. Epilepsia. 1998;39:S15-23.

  20. Canadian clobazam cooperative group. Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Epilepsia. 1991;32:407-16.

  21. Wolf P. Clobazam in drug-resistant patients with complex partial seizures. En: Hindmarch I, Stonier PO, Trimble MR, eds. Clobazam. Human psychopharmacology and clinical application. International Congress and Symposium. Series No. 74. London: Royal Society of Medicine; 1985. p. 167-71.

  22. Shorvon SD. Benzodiacepines: clobazam. In: Levy RH, Mattson RH, Meddrum BS, eds. Antiepileptic drugs. New York: Raven Press; 1995. p. 763-77.

  23. Keene DL, Whiting S, Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci. 1990;17:317-9.

  24. Koeppen D, Baruzzi A, Cappoza M, Chauvel P, Courjon J, Favel P, et al. Clobazam in therapy-resistant patients with partial epilepsy: a double-blind placebo-controlled crossover study. Epilepsy. 1987;28:495-506.

  25. Baruzzi A, Michelucci R, Tassinari CA. Nitrazepam. In: woodburg DM, Penry JK, Pippenger CE, eds. Antiepileptic drugs. New York: Raven Press; 1982. p. 753-69.

  26. Glauser TA, Ayala R, Elterman RD, Mitchell WG, van Orman CB, Gauer LJ, et al. Double-blind placebo controlled trial of adjunctive levetiracetam in pediatric partial seizure. Neurology. 2006;66:1654-60.

  27. Pina Garza JE, Schiemann-Delgado J, Yang H, Duncan B, Hada J, Hunter SJ. Adjunctive levetiracetam in patients age 1 month to d» 4 years with partial-onset seizures: subpopulation analysis of a prospective, open-label extension study of up to 48 weeks. Clin Ther. 2010;32:1935-50.

  28. Oguni H. Treatment of benign focal epilepsies in children: when and how should be treated? Brain Dev. 2011;33:207-12.

  29. Shields WD, Snead OC. Benign epilepsy with centrotemporal spikes. Epilepsia. 2009;50 suppl 8:10-5.

  30. Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia. 1998;39(suppl 3):S2-S10.

  31. Dalla Bernardina B, Sgrò V, Fejerman N. Epilepsie à pointes centro-temporales et síndromes apparentés. In: Roger J, Bureau M, Dravet Ch, Genton P, Tassinari CA, Wolf P, eds. Les syndromes épileptiques de l'enfant et de l'adolescent. 4ème edn. Montrouge: John Libbey Eurotext Ltd; 2005. p. 203-25.

  32. Coppola G, Franzoni E, Verrotti A, Garone C, Sarajija J, Operte FF, et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial. Brain Dev. 2007;29:181-4.

  33. Guerreiro MM, Vigonius U, Pohlmann H, de Manreza ML, Fejerman N, Antoniuk SA, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. 1997;27:205-13.

  34. Wheless JW, Neto W, Wang S, and the EPMN-105 Study Group. Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in children with newly diagnosed epilepsy. J Child Neurol. 2004;19:135-41.

  35. Thilothammal N, Banu K, Katnam RS. Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double-blind study. Indian Pediatr. 1996;33:549-55.

  36. Perucca E. Pharmacological and therapeutic properties of valproate. A summary after 35 years of clinical experience. CNS Drugs. 2002;16:695-714.

  37. Dreifuss FE, Sato S. Clonazepam. In: Woodbury DM, Penry JK, Pippenger CE, eds. Antiepileptic drugs. New York: Raven Press; 1982. p. 737-52.

  38. Hanson RA, Menkes JH. A new anticonvulsant in the management of minor motor seizures. Dev Med Child Neurol. 1972;14:3-14.

  39. Dreifuss FE, Penry JK, Rose SW, Kupferberg HJ, Pyken P, Sato S. Serum clonazepam concentrations in children with absence seizure. Neurology. 1975;25:225-58.

  40. Wray CD, Benke TA. Effect of price increase of adrenocorticotropic hormone on treatment practices of infantile spasms. Pediatr Neurol. 2010;43:163-6.

  41. Bobele GB, Bodensteiner JB. The treatment of infantile spams by child neurologists. J Child Neurol. 1994;9:432-5.

  42. Mackay MT, Weiss SK, Adams-Webber T, Ashwal S, Stephens D, Ballaban-Gill R, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology. 2004;62:1668-81.

  43. Kossoff EH. Infantile spasms. Neurologist. 2010;16:69-75.

  44. Lux AL, Edwards SW, Hancock, Johnson AL, Kennedy CR, Newton RW, et al. The United Kingdom Infantile spasms. Study comparing vigabatrin with prednisone or tetracosactide at 14 days. A multicentre, randomized controlled trial. Lancet. 2004;364:1773-8.

  45. Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomized trial. Lancet Neurol. 2005;4:712-7.

  46. Chiron C, Dumas C, Jambaque I, Mumford J, Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. 1997;26:389-95.

  47. Chiron C, Dulac O, Beaumont D, Palacios L, Pajot N, Mumford J, et al. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol. 1991;6(Supp 2):52-9.

  48. Prats JM, Garaizar C, Rua MJ, García-Nieto ML, Madoz P. Infantile spasms treated with high doses of sodium valproate: initial response and follow-up. Developmental Medicine on Child Neurology. 1991;33:617-25.

  49. Chamberlain MC. Nitrazepam for refractory infantile spasms and the Lennox-Gastaut syndrome. Journal of Child Neurology. 1996;11:31-4.

  50. Zou LP, Lin Q, Quin J, Cai FC, Liu ZS, Mix E. Topiramate study Group. Evaluation of open-label topiramate as primary or adjunctive therapy in infantile spasms. Clin Neuropharmacol. 2008;31:86-92.

  51. Buoni S, Zannolli R, Strambi M, Fois A. Combined treatment with vigabatrin and topiramate in West syndrome. Journal of Child Neurology. 2004;19:385-6.

  52. Conry JA. Pharmacologic treatment of the catastrophic epilepsies. Epilepsia. 2004;45:12-6.

  53. Yanagaki S, Oguni H, Yoshii K, Hayashi K, Imai K, Funatsuka M, Osawa M. Zonisamide for West syndrome: a comparison of clinical responses among different titration rate. Brain Dev. 2005;27:286-90.

  54. Chiron C, Dulac O. The pharmacologic treatment of Dravet syndrome. Epilepsia. 2011;52 suppl 2:72-5.

  55. Dravet Ch, Bureau M, Oguni H, Fukuyama Y, Cokar O. L'épilepsie myoclonique severe du nourison (syndrome de Dravet). En: Roger J Bureau M, Dravet Ch, Genton P, Tassinari CA, Wolf P, eds. Les syndromes épileptiques de l'enfant et de l'adolescent. 4ème edn. Montrouge: John Libbey Eurotext Ltd; 2005. p. 89-114.

  56. Nieto-Barrera M, Candau R, Nieto-Jiménez M, Cornera A, Ruiz del Portal L. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure. 2000;9:590-4.

  57. Coppola G, Capovilla G, Montagnini A, Romeo A, Spano M, Tortorella G, Veggiotti P, Viri M, Pascotto A. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res. 2002;49:45-8.

  58. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and severe aggravation in severe myoclonic epilepsy. Epilepsia. 1998;39:508-12.

  59. Perez J, Chiron C, Musial C, Rey E, Blehaut H, d'Athis P, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999;40:1618-26.

  60. Chiron C, Marchand MC, Tran A, Rey E, d'Athis P, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomized placebo-controlled syndrome-dedicated trial. The Lancet. 2000;356:1638-42.

  61. Genton P, Guerrini R, Dravet C. The Lennox-Gastaut syndrome. In: Meinardi H, ed. Handbook of clinical Neurology. The epilepsies. Part II. Amsterdam: Elsevier Science; 2000. p. 211-22.

  62. Trevathan E. Infantile spasms and Lennox-Gastaut syndrome. Journal of Child Neurology. 2002;17(suppl 2):259-322.

  63. Arzimanoglou A, Kulak I, Bidaut-Mazel C, Baldy-Moulinier M. Optimal use of lamotrigine in clinical practice: results of an open multicenter trial in refractory epilepsy. Revue Neurologique. 2001;157:525-36.

  64. Beaumanoir A, Blume W. Le syndrome de Lennox-Gastaut. En: Roger J, Bureau M, Dravet Ch, Genton P, Tassinari CA, Wolf P. Les syndromes épileptiques de l'enfant et de l'adolescent. 4ème edn. Montrouge: John Libbey Eurotext Ltd; 2005. p. 125-48.

  65. Sachdeo RC, Glauser TA, Ritter F, Lim P, Pleder G. The topiramate YÖ study goup. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology. 1999;52:1882-7.

  66. Eriksson AS, Nergardh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia. 1998;39:495-501.

  67. De los Reyes EC, Sharp GB, Williams JP, Hale SE. Levetiracetam in the treatment of Lennox-Gastaut syndrome. Pediatr Neurol. 2004;30:54-6.

  68. Glauser T, Kluger G, Sachedo R, Krauss G, Perdomo G, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70:1950-8.

  69. Coppola G, Grosso S, Franzoni E, Veggiotti P, Zamponi N, Parisi P, et al. Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience. Seizure. 2010;19:587-91.

  70. Van Rijckevorsel K, Delire M, Schmitz-Moorman W, Wieser HG. Treatment of refractory epilepsy with intravenous immunoglobulins. Results of the first double blind/dose finding clinical study. Inter J Clin Lab Res. 1994;24:162-6.

  71. Feasby T, Banwell B, Benstead T, Bril V, Brouwers M, Freedman M, Hahn A. Guidelines on the use of intravenous immunoglobulin for neurologic conditions. Transfus Med Rev. 2007;21:S57-S107.

  72. Nickels K, Wirrell E. Electrical status epilepticus in sleep. Semin Pediatr Neurol. 2008;15:50-60.

  73. Inutsuka M, Kobayashi K, Oka M, Hattori J, Ohtsuka Y. Treatment of epilepsy with electrical status epilepticus during slow sleep and its related disorders. Brain Dev. 2006;28:281-6.

  74. Mikati MA, Shamseddine AN. Management of Landau-Kleffner syndrome. Paediatr Drugs. 2005;7:377-89.

  75. De Negri M, Baglietto MG, battaglia FM, Gaggero R, Pessagno A, Recanati L. Treatment of electrical status epilepticus by short diazepam cycles after DZP rectal bolus test. Brain Dev. 1995;17:330-3.

  76. Kramer U, Sagi L, Goldberg-Stern H, Zelnik N, Nissen-Korn A, Ben-Zeev B. Clinical spectrum and medical treatment of children with electrical status epilepticus in sleep (ESES). Epilepsia. 2009;50:1517-24.

  77. García JJ. Disfunción neurocognitiva en el síndrome de estado de mal eléctrico durante el sueño lento: ¿podemos modificar la evolución natural del síndrome con un tratamiento farmacológico precoz? Rev Neurol. 2010;50 (Supl 3):S37-S47.

  78. Chhun S, Troude P, Villeneuve N, Soufflet C, Napuri S, Motte J, et al. A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes: continuous spikes and waves during sleep is definitely a target. Seizure. 2011;20:320-5.

  79. Sinclair DB. Prednisone therapy in pediatric epilepsy. Pediatr Neurol. 2003;28:194-8.

  80. Mikati M, Fayad M, Choueri R. IVIG in Landau-Kleffner syndrome. Pediatr Neurol. 1998;19:399-400.

  81. Lague LG, Silberstein J, Gillis PL, Casaer PJ. Successful use of a Intravenous immunoglobulins in Landau-Kleffner syndrome. Pediatr Neurol. 1998;18:165-8.

  82. Mikati MA, Saab R, Fayad MN, Choueiri RN. Efficacy of intravenous immunoglobulin in Landau-Kleffner syndrome. Pediatr Neurol. 2002;26:298-300.

  83. Guerrini R, Parmeggiani L, Bunanni P, Kaminska A, Dulac O. L'épilepsie myoclono-astatique. En: Roger J, Bureau M, Dravet Ch, Genton P, Tassinari CA, Wolf P, eds. Les syndromes épileptiques de l'enfant et de l'adolescent. 4ème edn. Montrouge: John Libbey Eurotext Ltd.; 2005. p. 115-24.

  84. Oguni H, Hayashi K, Imai K, Funetsuka M, Sakauchi M, Shirakawa S, et al. Idiopathic myoclonic-astatic epilepsy of early childhood. Myoclonic-astatic epilepsy of early childhood. Nosology based on electrophysiologic and long-term follow-up study of patients. Adv Neurol. 2005;95:157-74.

  85. Hirsch E, Panayiotopoulos P. Epilepsie-absences de l'enfance et syndromes apparentés. En: Roger J, Bureau M, Dravet Ch, Genton P, Tassinari CA, Wolf P, eds. Les syndromes épileptiques de l'enfant et de l' adolescent. 4ème edn. Montrouge: John Libbey Eurotext Ltd.; 2005. p. 315-36.

  86. Frank LM, Enlow T, Holmes GL, Manasco P, Concannon S, Chen C, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia. 1999;40:973-79.

  87. Mikati MA, Holmes GL. Lamotrigine in absence and primary generalized epilepsies. J Child Neurol. 1997;12(suppl):S29-S37.

  88. Schlumberg E, Chavez F, Palacios L, Rey E, Pajot N, Dulac O. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia. 1994;35:359-67.

  89. Coppola G, Auncchio G, Federico R, Carotenuto M, Pascotto N. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures:an open-label, randomized, parallel-group study. Epilepsia. 2004;45:1049-53.

  90. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47:1094-120.

  91. Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy. Expert opinion 2005. J Child Neurol. 2005;20 (Suppl 1):S1-S56.

  92. Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord. 2007;9:353-412.

  93. Penovich PE, Willmore LJ. Use of a new antiepileptic drug of an old one drug for treatment of absence epilepsy. Epilepsia. 2009;50 (Suppl 8):37-41.

  94. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010;362:790-9.

  95. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013;54:141-55.

  96. Piña-Garza JE, Schwarzman L, Wiegand F, Hulihan J. A pilot study of topiramate in childhood absence epilepsy. Acta Neurol Scand. 2011;123:54-9.

  97. Fattore C, Boniver C, Capovilla G, Cerminara C, Cittero A, Coppola G, et al. A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia. 2011;52:802-9.

  98. Auvin S, Chhun S, Berquin P, Panchel E, Delanöe C, Chiron C. Aggravation of absence seizure related to levetiracetam. Eur J Paediatr Neurol. 2011;15:508-11.

  99. Mantoan L, Walker M. Treatment options in juvenile myoclonic epilepsy. Curr Treat Options Neurol. 2011;13:355-70.

  100. Nicolson A, Marson AG. When the first antiepileptic drug fails in a patient with juvenile myoclonic epilepsy. Pract Neurol. 2010;10:208-18.

  101. Bodenstein-Sachar H, Gandelman-Marton R, Ben-Zeev B, Chapman J, Blatt I. Acta Neurol Scand. 2011;124:22-7.

  102. Verroti A, Loiacono G, Coppola G, Spalice A, Mohn A, Chiarelli F. Pharmacotheray for children and adolescents with epilepsy. Expert Opin Pharmacotherapy. 2011;12:175-94.




2020     |     www.medigraphic.com